MedPath

Influence of low-dose i.v. growth hormone treatment together with glutamine supplementation in late-phase critically ill patient after multiple injury. A pilot study. - AGHATA

Phase 1
Conditions
Prolonged phase of critical illness after severe multiple trauma
Registration Number
EUCTR2004-004727-36-CZ
Lead Sponsor
Charles University, 3rd Faculty of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Female
Target Recruitment
30
Inclusion Criteria

Multiple trauma patients admitted to Dept. of Anaesthesia and Criticla Care Medicine of Kralovske Vinohrady University Hospital, Prague. Age 18-60 years, both sexes, on the 4th day after injury expected to stay at least a week in the ICU. Written informed consent (given by the closest relative in inconcious subjects).
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Diabetes mellitus or other known endocrinopathy, gravidity, known allergy to growth hormone), head injury involving hypothalamo-pituitary region, treatment of immune suppresants of high-dose corticoids.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath